Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.